BioVersys AG (SIX: BIOV), a clinical-stage biopharmaceutical company developing novel antibacterial products for multi-drug resistant (MDR) infections, announced today that all proposals by its Board of Directors were approved by shareholders at the Annual General Meeting. The meeting, held in Basel, Switzerland, saw unanimous support for the 2025 annual report, financial statements, and board appointments, reflecting continued shareholder confidence in the company's mission.
Dr. Seng Chin Mah, Chairman of the Board, expressed gratitude: "On behalf of the Board of Directors and Management, I would like to thank our shareholders for their continued trust in us and for their unwavering support for the BioVersys mission. Having achieved FPFV for the global BV100 Phase 3 trial, we are completely focused on eventually bringing this therapeutic option to patients in dire need." He also acknowledged the contributions of Dr. William Jenkins, who stepped down from the board, and welcomed new member Ms. Simona Skerjanec.
The approved agenda items included the re-election of Seng Chin Mah as Chairman, along with the re-election of David Hunstad, Marc Gitzinger, Marina von Schonau, and Ulrik Schulze. Ms. Simona Skerjanec was elected as a new member. Shareholders also approved the maximum aggregate compensation for the Board of Directors until the 2027 AGM and for the Executive Committee for the 2027 financial year.
BioVersys focuses on serious life-threatening infections caused by MDR bacteria, leveraging its TRIC and Ansamycin Chemistry platforms to develop candidates that overcome resistance mechanisms. The company's lead program, BV100, targets Acinetobacter baumannii nosocomial infections and is in Phase 3. Another key candidate, alpibectir for tuberculosis, is in Phase 2 in collaboration with GlaxoSmithKline (GSK) and a consortium including the University of Lille, France.
The approval of all board proposals signals strong shareholder alignment with BioVersys' strategic direction. As the company progresses its pipeline, the outcomes of the BV100 Phase 3 trial and alpibectir studies could have significant implications for patients with limited treatment options. The rise of antimicrobial resistance continues to be a global health crisis, and successful development of these therapies would address a critical unmet need.
Associated documents, including the Annual Report and AGM details, are available on the company's website: Annual Report and AGM.
